sb 203580 has been researched along with birb 796 in 25 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 137 | 5 | 80 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breitfelder, S; Cirillo, P; Gilmore, T; Graham, AG; Hickey, E; Klaus, B; Madwed, J; Moriak, M; Moss, N; Pargellis, C; Pav, S; Proto, A; Regan, J; Swinamer, A; Tong, L; Torcellini, C | 1 |
| Capolino, A; Cirillo, PF; Gilmore, T; Graham, AG; Hickey, E; Kroe, RR; Madwed, J; Moriak, M; Moss, N; Nelson, R; Pargellis, CA; Regan, J; Swinamer, A; Torcellini, C; Tsang, M | 1 |
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Ahrens, GM; Hering, JS; Karcher, SC; Laufer, SA; Niess, R | 1 |
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Boman, E; Ceide, SC; Chang, CD; Dahl, R; Dalesandro, D; Delaet, NG; Erb, E; Ernst, JT; Gibbs, A; Kahl, J; Kessler, L; Larson, CJ; Lundström, J; Miller, S; Montalban, AG; Nakanishi, H; Roberts, E; Saiah, E; Sullivan, R; Wang, Z | 1 |
| Domeyer, DM; Hauser, DR; Kinkel, K; Laufer, SA; Liedtke, AJ | 1 |
| Groebe, D; Hajduk, PJ; Kifle, L; Merta, PJ; Sarris, K; Sun, C; Swann, SL | 1 |
| Boman, E; Ceide, SC; Chang, CD; Dahl, R; Dalesandro, D; Delaet, NG; Erb, E; Ernst, JT; Gibbs, A; Kahl, J; Kessler, L; Kucharski, J; Larson, CJ; Lum, C; Lundström, J; Miller, S; Montalban, AG; Nakanishi, H; Roberts, E; Saiah, E; Sullivan, R; Urban, J; Wang, Z | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Bauer, SM; Boeckler, FM; Fischer, S; Grütter, C; Koeberle, SC; Laufer, SA; Mayer-Wrangowski, SC; Niess, R; Rauh, D; Storch, K; Wentsch, HK; Zimmermann, M | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bhat, R; Canan, S; Chojnowski, A; Goldberg, R; Hawryluk, N; Khetani, V; Kreiss, T; Mortensen, D; Prorok, M; Rotella, DP; Siekierka, JJ; Tummalapalli, SR; Zeldis, J | 1 |
| Anderson, WF; Arancio, O; Chico, LW; Minasov, G; Pelletier, JC; Roy, SM; Van Eldik, LJ; Watterson, DM | 1 |
| Gagnon, AI; Jia, Y; Quinn, CM; Talanian, R | 1 |
| Kok, JJ; Loomans, EE; Nelissen, RL; van der Lee, MM; Zaman, GJ | 1 |
| Brown, A; Foxwell, BM; Page, TH; Ray, KP; Timms, EM | 1 |
| Aoki, T; Arai, T; Hayashi, S; Hirokawa, H; Inoue, H; Kainoh, M; Kawai, H; Koga, Y; Meguro, H; Ohno, M; Oshida, K; Suyama, K | 1 |
| Falck, D; Giera, M; Honing, M; Kool, J; Niessen, WM; Rahimi Pirkolachachi, F | 1 |
| Chang, G; Li, Y; Lu, K; Ye, L; Zhang, D; Zhang, P | 1 |
| Hirose, E; Ishimaru, Y; Narahara, S; Sakamoto, A; Sugiuchi, H; Yamaguchi, R; Yamaguchi, Y; Yamamoto, T | 1 |
| Dastidar, SG; Diwan, M; Najmi, AK; Singh, RK | 1 |
1 review(s) available for sb 203580 and birb 796
| Article | Year |
|---|---|
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
Topics: Animals; Brain; Cognitive Dysfunction; Humans; Inflammation; Nervous System Diseases; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors | 2019 |
24 other study(ies) available for sb 203580 and birb 796
| Article | Year |
|---|---|
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Cell Line; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Enzyme Inhibitors; Female; Fluorescence; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Models, Molecular; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Protein Binding; Pyrazoles; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Urea | 2002 |
Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
Topics: Animals; Cell Line; Crystallography, X-Ray; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Heating; Humans; In Vitro Techniques; Ligands; Lipopolysaccharides; Mice; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinases; Naphthalenes; Protein Binding; Protein Denaturation; Pyrazoles; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Urea | 2003 |
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Design; Humans; Molecular Structure; Oxepins; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Structure-Activity Relationship | 2006 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Topics: Adenosine Triphosphate; Allosteric Site; Amides; Animals; Binding Sites; Cells, Cultured; Crystallography, X-Ray; Drug Design; Humans; Lipopolysaccharides; Models, Molecular; Molecular Structure; Monocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2008 |
Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.
Topics: Drug Design; Humans; Imidazoles; Molecular Mimicry; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Structure-Activity Relationship | 2008 |
Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
Topics: Adenosine Triphosphate; Binding Sites; Computer Simulation; Crystallography, X-Ray; Fluorescence Resonance Energy Transfer; Kinetics; Mitogen-Activated Protein Kinase 14; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Structure-Activity Relationship | 2010 |
Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.
Topics: Administration, Oral; Allosteric Site; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cell Line; Computer Simulation; Humans; p38 Mitogen-Activated Protein Kinases; Protein Binding; Protein Kinase Inhibitors; Rats; Structure-Activity Relationship | 2010 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Dibenzocycloheptenes; Hydrophobic and Hydrophilic Interactions; Lipopolysaccharides; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Protein Binding; Solubility; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis.
Topics: | 2018 |
Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery.
Topics: Adenosine Triphosphate; Catalysis; Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Imidazoles; Kinetics; Naphthalenes; Phosphotransferases; Pyrazoles; Pyridines; Reproducibility of Results; Time Factors | 2006 |
Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Topics: Animals; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Green Fluorescent Proteins; Humans; Imidazoles; Kinetics; Mitogen-Activated Protein Kinase 14; Molecular Structure; Naphthalenes; Peptide Fragments; Protein Binding; Protein Kinase Inhibitors; Protein Transport; Pyrazoles; Pyridines; Recombinant Fusion Proteins; Structure-Activity Relationship; Surface Plasmon Resonance | 2006 |
Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: does variable inhibition of interleukin-6 production limit effectiveness in vivo?
Topics: Arthritis, Rheumatoid; Blotting, Western; Cells, Cultured; Cytokines; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Interleukin-6; Macrophages; Monocytes; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazoles; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane | 2010 |
Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.
Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Cytochrome P-450 Enzyme System; Drug Design; Drug Evaluation, Preclinical; Humans; Imidazoles; Lipopolysaccharides; Liver; Mice; Mitogen-Activated Protein Kinase 14; Naphthalenes; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrazoles; Pyridines; Pyrimidines; Tumor Necrosis Factor-alpha; Urea | 2012 |
Comparison of (bio-)transformation methods for the generation of metabolite-like compound libraries of p38α MAP kinase inhibitors using high-resolution screening.
Topics: Bacillus megaterium; Benzamides; Chemistry, Pharmaceutical; Cytochrome P-450 Enzyme System; High-Throughput Screening Assays; Humans; Hydrogen Peroxide; Imidazoles; Indoles; Light; Liver; Microsomes, Liver; Mitogen-Activated Protein Kinase 14; Naphthalenes; Oxygen; Photochemistry; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2014 |
Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Cell Hypoxia; Cell Line; Cell Survival; Creatine Kinase, MB Form; Enzyme-Linked Immunosorbent Assay; Exenatide; Glucose; Glucose Transporter Type 1; Imidazoles; Intercellular Signaling Peptides and Proteins; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinase 12; Myocytes, Cardiac; Naphthalenes; Peptides; Protective Agents; Proteins; Pyrazoles; Pyridines; Rats; Signal Transduction; Venoms | 2015 |
Mechanism of interleukin-13 production by granulocyte-macrophage colony-stimulating factor-dependent macrophages via protease-activated receptor-2.
Topics: Butadienes; Calcium; Calcium Channel Blockers; Cell Adhesion; Cell Differentiation; Dose-Response Relationship, Drug; Flavonoids; Gallic Acid; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Interleukin-13; Leukocyte Elastase; Macrophages; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Monocytes; Naphthalenes; Nitriles; p38 Mitogen-Activated Protein Kinases; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor, PAR-2; Signal Transduction | 2015 |
Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
Topics: Anti-Inflammatory Agents; Biomarkers; Cell Survival; Cells, Cultured; Cytokines; Hep G2 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inflammation; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; MAP Kinase Kinase 4; Naphthalenes; Nitric Oxide; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; THP-1 Cells; U937 Cells | 2018 |